Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.
The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, STRO declined 3.52%, reflecting a moderate negative market reaction. Argus tracked a trough of -20.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $86M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.
The live webcast will be held on Wednesday, November 12, 2025, starting at 7:00AM PT / 10:00AM ET.
Webcast Information:
To access the live audio webcast, please go to https://ir.sutrobio.com/news-events/ir-calendar. An archived replay of the webcast will be available on the Company’s website following the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
When is Sutro Biopharma's (STRO) virtual Research & Development Day?
How can investors access the Sutro (STRO) live webcast on November 12, 2025?
Will Sutro (STRO) provide a replay of the November 12, 2025 R&D Day webcast?
What topics will Sutro Biopharma (STRO) cover during the R&D Day on November 12, 2025?
What time should East Coast investors tune in to Sutro (STRO) R&D Day on November 12, 2025?
